Evidence map›Paper›PMID 31888931›Full record

ArticleBMJ open2019

AMEND study protocol: a case-control study to assess the long-term impact of invasive meningococcal disease in Australian adolescents and young adults.

Helen Marshall, Mark McMillan, Bing Wang, Robert Booy, Hossein Afzali, Jim Buttery, Christopher C Blyth, Peter Richmond, David Shaw, David Gordon and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03798574 (The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03798574 completednot on this map

The Long-term Impact of Invasive Meningococcal Disease in Australian Adolescents and Young Adults

TypeobservationalSponsorUniversity of AdelaideRan2016 to 2022Enrolled98ConditionsMeningococcal Infections, Neisseria Meningitis Sepsis, Neisseria Infection
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 9 institutions in 1 country.

Helen MarshallVaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia helen.marshall@adelaide.edu.au.ORCID 0000-0003-2521-5166
Mark McMillanVaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia.ORCID 0000-0002-6490-7707
Bing WangVaccinology and Immunology Research Trials Unit, Women's and Children's Health Network, Adelaide, South Australia, Australia.
Robert BooyThe Discipline of Child and Adolescent Health, The Children's Hospital at Westmead, University of Sydney Medical School, Westmead, New South Wales, Australia.
Hossein AfzaliSchool of Public Health, Univeristy of Adelaide, Adelaide, South Australia, Australia.
Jim ButteryDepartment of Paediatrics, Royal Children's Hospital, Melbourne, Victoria, Australia.
Christopher C BlythDepartment of Infectious Diseases, Perth Children's Hospital, Perth, Western Australia, Australia.
Peter RichmondSchool of Medicine, University of Western Australia and Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kid's Institute, Perth, Western Australia, Australia.
David ShawInfectious Diseases Service, Central Health Service, SA Health, Adelaide, South Australia, Australia.
David GordonMicrobiology and Infectious Diseases, Flinders Medical Centre, Bedford Park, South Australia, Australia.
Belinda BartonChildren's Hospital Education Research Institute (CHERI), The Children's Hospital at Westmead, Westmead, New South Wales, Australia.ORCID 0000-0002-3157-2031
Women's and Children's Health Network · AUChildren's Hospital at Westmead · AUFlinders Medical Centre · AUPrincess Margaret Hospital for Children · AURoyal Children's Hospital · AUSA Health · AUThe Kids Research Institute Australia · AUThe University of Adelaide · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInvasive meningococcal disease (IMD) primarily causes disease in young children and adolescents and can cause long-term disability. Many countries are considering implementation of meningococcal B and/or meningococcal ACWY vaccines to control meningococcal disease. Estimating the cost-effectiveness of meningococcal vaccine programme is hampered due to a lack of good quality costing and burden of disease data. This study aims to address this evidence gap by assessing the clinical, physical, neurocognitive, economic and societal impact of IMD on adolescents and young adults. METHODS AND ANALYSIS: A case-control study of 64 participants with confirmed IMD (15-24 years 11 months at time of disease) and 64 control participants (17-34 years 11 months) will be conducted in Australia from 2016 to 2020. All participants will undergo a neurocognitive assessment, full medical examination, pure tone audiometry assessment and complete quality of life and behavioural questionnaires. Meningococcal cases will be assessed 2-10 years posthospitalisation and a subset of cases will be interviewed to explore in depth their experiences of IMD and its impact on their life. Primary outcome measures include general intellectual functioning from the Wechsler Adult Intelligence Scale and overall quality of life from the Health Utilities Index. Secondary outcome measures include academic achievement, executive functioning, behaviour, hearing, psychological and physical functioning. Outcome measures will be compared between cases and controls using independent t-tests or ORs, or if any significant confounders are identified, adjusted analyses (analysis of covariance or adjusted ORs) will be conducted. Thematic analysis will be used to analyse transcribed interviews and a costing model will be used to project lifetime costs. ETHICS AND DISSEMINATION: The Adolescent MENingococcal Disease (AMEND) study has been approved by the Human Research Ethics Committee of the Women's and Children's Health Network (HREC/14/WCHN/024). The results will be disseminated via peer-reviewed publications, conference presentations, study participants, and meningococcal and meningitis foundations. TRIAL REGISTRATION NUMBER: NCT03798574.

Indexed as

AdolescentAustraliaCase-Control StudiesCost of IllnessFemaleHealth Care CostsHearing LossHumansMaleMeningococcal InfectionsNeuropsychological TestsQuality of LifeRetrospective StudiesSurveys and QuestionnairesYoung Adultadolescentshealth economicsimmunisation programsmeningococcal diseaseneurocognitivesequelaeyoung adults

Identifiers

PMID31888931
PMCPMC6937050
OpenAlexW2998247251

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.